Health care financing and international health policies

Health care financing and international health policies

CRA helps clients to understand and respond to global policy and healthcare financing issues and their links with political objectives around fiscal sustainability and health outcomes.

There is great disparity between the policies and challenges of developed countries, with well-established healthcare systems, and those of emerging middle-income countries that are increasing healthcare spending to support more universal health coverage. CRA works with clients to examine how different countries finance healthcare and the impact this has for access to medicines and in commercial terms for companies.


Models of healthcare financing

  • Analysis of the healthcare financing environment in a country and the impact this has on the functioning of the local market
  • Assessment of sources of finance, contribution mechanisms and the organizations responsible for health care funding

Impact of Universal Health Coverage

  • Understanding the development of Universal Health Coverage (UHC) as a core priority for middle income countries as endorsed by WHO and how this affects access to medicines
  • Assessment of how UHC may be financed and implemented in different countries and the implications for industry

Access to medicines in low and middle income countries

  • Review of drug pricing policies as a barrier to access in emerging markets and low income countries
  • Helping companies and governments to anticipate trends in healthcare and access to medicines
  • Economic analysis to influence debate around access to medicines in developing countries

International trade agreements

  • Assessment of regional or bilateral Free Trade Agreements (FTAs) in developing countries
  • Review of implications of the Trans-Atlantic Trade and Investment Partnership (TTIP) negotiations and other trade discussions with emerging markets such as China

Evolution of regulatory trends

  • Advice on varying policy and regulatory environments at national and international level, their effectiveness and implications for clients
  • Comparison between countries and regions in terms of medicines regulatory authorities and formal requirements for registering medicines
  • Implications for access in emerging markets

Recent engagements

  • The transition to universal healthcare coverage: lessons for managing the pharmaceutical budget
  • Assessment of EU-level policy intervention in support of tiered pricing schemes for DG Trade of the European Commission
  • Assessment of how value is put on clinical trials and how this is evidenced
  • Report on how different countries have implemented pharmacovigilance for biotherapeutic medicines
  • Development of a set of possible funding mechanisms for the WHO prequalification (PQ) programme


Tim Wilsdon
Vice President